https://transhumanist.ru/index.php?action=history&feed=atom&title=DIP2A 2026-04-10T21:33:12Z История изменений этой страницы в вики MediaWiki 1.43.6 https://transhumanist.ru/index.php?title=DIP2A&diff=6378&oldid=prev 2021-05-12T15:27:24Z

<p>Новая страница: «Disco-interacting protein 2 homolog A (EC 6.2.1.1) (DIP2 homolog A) [C21orf106] [DIP2] [KIAA0184] ==Publications== {{medline-entry |title=Blocking the <a href="/FSTL1" title="FSTL1">FSTL1</a>...»</p> <p><b>Новая страница</b></p><div>Disco-interacting protein 2 homolog A (EC 6.2.1.1) (DIP2 homolog A) [C21orf106] [DIP2] [KIAA0184]<br /> <br /> ==Publications==<br /> <br /> {{medline-entry<br /> |title=Blocking the [[FSTL1]]-[[DIP2A]] Axis Improves Anti-tumor Immunity.<br /> |pubmed-url=https://pubmed.ncbi.nlm.nih.gov/30110636<br /> |abstract=Immune dysfunction is a strong factor in the resistance of cancer to treatment. Blocking immune checkpoint pathways is a promising approach to improve anti-tumor immunity, but the clinical efficacies are still limited. We previously identified follistatin-like 1 ([[FSTL1]]) as a determinant of immune dysfunction mediated by mesenchymal stromal/stem cells (MSCs) and immunoregulatory cells. Here, we demonstrate that blocking [[FSTL1]] but not immune checkpoint pathways significantly suppresses cancer progression and metastasis in several mouse tumor models with increased MSCs. Expression of [[DIP2A]] (the receptor of [[FSTL1]]) in tumor cells is critical for [[FSTL1]]-induced immunoresistance. [[FSTL1]]/[[DIP2A]] co-positivity in tumor tissues correlates with poor prognosis in NSCLC patients. Thus, breaking the [[FSTL1]]-[[DIP2A]] axis may be a useful strategy for successfully inducing anti-tumor immunity.<br /> |mesh-terms=* Animals<br /> * Carcinoma, Non-Small-Cell Lung<br /> * Carrier Proteins<br /> * Case-Control Studies<br /> * Cell Line, Tumor<br /> * Cell Movement<br /> * Cell Proliferation<br /> * Disease Progression<br /> * Female<br /> * Follistatin-Related Proteins<br /> * Gene Expression Regulation, Neoplastic<br /> * Humans<br /> * Immunity, Innate<br /> * Lung Neoplasms<br /> * Male<br /> * Mesenchymal Stem Cells<br /> * Mice<br /> * Mice, Inbred BALB C<br /> * Mice, Inbred C57BL<br /> * Nuclear Proteins<br /> * Prognosis<br /> * RNA, Small Interfering<br /> * Signal Transduction<br /> * Survival Analysis<br /> * Tumor Burden<br /> * Xenograft Model Antitumor Assays<br /> |keywords=* FSTL1<br /> * aging<br /> * antibody<br /> * cancer metastasis<br /> * immune checkpoint<br /> * immune exhaustion<br /> * immunosuppression<br /> * lung cancer<br /> * mesenchymal stromal/stem cells<br /> |full-text-url=https://sci-hub.do/10.1016/j.celrep.2018.07.043<br /> }}</div>

OdysseusBot